Project Details
Description
A 26 week open label, flexible dose trial of Asenapine extension treatment to PO6107 in Pediatric Acute Manic or mixed episodes associated with BP1 disorder PO5898
| Status | Finished |
|---|---|
| Effective start/end date | 8/1/12 → 5/30/14 |
Funding
- SCHERING-PLOUGH CORPORATION
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.